-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $8 Price Target

Benzinga·11/18/2026 12:12:16
Listen to the news
HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $8 price target.